Possible Reversal of Carbon Tetra Chloride-induced Liver Fibrosis in Sprague Dawley Rats treated with Stromal Vascular Fraction and Activated Platelet Rich Plasma
Abstract
Stromal vascular fraction (SVF) is considered a promising source of stem cells, but potential of treatment of damaged liver has not been fully explored. Aim: In this study, we sought to evaluate the hepato-regenerative effect of SVF combined with activated platelet rich plasma (aPRP) on carbon tetrachloride (CCl4) induced hepatic injury in Sprague Dawley (SD) rats. Liver fibrosis was induced using CCl4 in 30 SD rats. Sixteen rats survived and were divided into two groups – control and treated. SVF and aPRP were prepared by standard methods from three normal donor rats. Combination SVF-aPRP was administered intravenously via the lateral tail vein in treated group animals, on Day 0, 7 and 14. Normal saline of same dose volume was administered to the control group. AST and ALT levels were monitored throughout the study duration of 28 days. Gross and histopathological analysis of liver was performed post sacrifice on Day 28. Decrease in the ALT/AST levels over the duration of study was observed in both control and treated groups, with a statistically significant reduction in AST/ALT levels between Control ad Treated groups on Day 28. Gross morphological evaluation, fibrosis and cirrhosis grades also showed reduction between control and treated groups. Observations of enzyme levels, gross and histopathological analyses revealed a reduction in severity of liver fibrosis in the treated group. However, we have identified additional parameters that need to be evaluated to corroborate these research findings.
Keywords:
Stromal Vascular Fraction, SD Rat, Activated platelet rich plasma, Carbon Tetrachloride, Liver FibrosisDOI
https://doi.org/10.25004/IJPSDR.2022.140215References
Asrani SK, Devarbhavi H, Eaton J, Kamath PS. Burden of liver diseases in the world. J Hepatol [Internet]. 2019;70(1):151–71. Available from: http://dx.doi.org/10.1016/j.jhep.2018.09.014
Brenner DA. Reversibility of liver fibrosis. Gastroenterol Hepatol (N Y). 2013;9(11):737–9.
Schuppan D, Afdhal NH. Liver cirrhosis. Lancet [Internet]. 2008 [cited 2022 Apr 7];371(9615):838–51. Available from: https:// pubmed.ncbi.nlm.nih.gov/18328931/
Bateman ME, Strong AL, Gimble JM, Bunnell BA. Concise Review: Using fat to fight disease: A systematic Review of nonhomologous adipose-derived stromal/stem cell therapies. Stem Cells [Internet]. 2018;36(9):1311–28. Available from: http://dx.doi.org/10.1002/ stem.2847
Bataller R, Brenner DA. Liver fibrosis. J Clin Invest [Internet]. 2005 [cited 2022 Apr 7];115(2):209–18. Available from: https://pubmed. ncbi.nlm.nih.gov/15690074/
Yovchev MI, Xue Y, Shafritz DA, Locker J, Oertel M. Repopulation of the fibrotic/cirrhotic rat liver by transplanted hepatic stem/ progenitor cells and mature hepatocytes: Yovchev et al. Hepatology [Internet]. 2014;59(1):284–95. Available from: http://dx.doi. org/10.1002/hep.26615
Home - ClinicalTrials.gov [Internet]. Clinicaltrials.gov. [cited 2022 Apr 7]. Available from: https://clinicaltrials.gov/
Qomi T, Sheykhhasan R. Adipose-derived stromal cell in regenerative medicine: A review. World J Stem Cells. 2017;9(8):107–17.
Han S, Sun HM, Hwang K-C, Kim S-W. Adipose-derived stromal vascular fraction cells: Update on clinical utility and efficacy. Crit Rev Eukaryot Gene Expr [Internet]. 2015;25(2):145–52. Available from: http://dx.doi.org/10.1615/critreveukaryotgeneexpr.2015013057
Chen G, Jin Y, Shi X, Qiu Y, Zhang Y, Cheng M, et al. Adipose-derived stem cell-based treatment for acute liver failure. Stem Cell Res Ther [Internet]. 2015 [cited 2022 Apr 7];6(1):40. Available from: http:// dx.doi.org/10.1186/s13287-015-0040-2
Kim JY, Choi JH, Jun JH. Enhanced PRL-1 expression in placentaderived mesenchymal stem cells accelerates hepat ic funct ion via mitochondrial dynamics in a cirrhotic rat model. Stem Cell Res Ther. 2020;11(1).
Carbone A, Rucc M, Annacontini L, Portincasa A, &conese M. Adipose-derived stem cells and platelet-rich plasma: inputs for regenerative medicine. Medical Research Archives. 2017;(5).
Mafi A, Dehghani F, Moghadam A, Noorafshan A, Vojdani Z, Talaei- Khozani T. Effects of platelet-rich plasma on liver regeneration in CCl4-induced hepatotoxicity model. Platelets [Internet]. 2016;27(8):771–6. Available from: http://dx.doi.org/10.1080/09 537104.2016.1184749
Tobita M, Tajima S, Mizuno H. Adipose tissue-derived mesenchymal stem cells and platelet-rich plasma: stem cell transplantation methods that enhance stemness. Stem Cell Res Ther [Internet]. 2015;6(1):215. Available from: http://dx.doi.org/10.1186/s13287- 015-0217-8
Fujii T, Fuchs BC, Yamada S, Lauwers GY, Kulu Y, Goodwin JM, et al. Mouse model of carbon tetrachloride induced liver fibrosis: Histopathological changes and expression of CD133 and epidermal growth factor. BMC Gastroenterol [Internet]. 2010;10(1):79. Av a i l a ble f r om : ht t p://d x . doi . or g /10 .118 6/1471-230X- 10-79
Palumbo P, Lombardi F, Siragusa G, Cifone MG, Cinque B, Giuliani M. Methods of isolation, characterization and expansion of human adipose-derived stem cells (ASCs): An overview. Int J Mol Sci [Internet]. 2018;19(7). Available from: http://dx.doi.org/10.3390/ ijms19071897
Dhurat R, Sukesh M. Principles and methods of preparation of platelet-rich plasma: A review and author’s perspective. J Cutan Aesthet Surg [Internet]. 2014;7(4):189–97. Available from: http:// dx.doi.org/10.4103/0974-2077.150734
Truong HN, Nguyen HN, Nguyen TKN, Le MH, Tran HG, Huynh N, et al. Establishment of a standardized mouse model of hepatic fibrosis for biomedical research. Biomed Res Ther [Internet]. 2014;1(2). Available from: http://dx.doi.org/10.7603/s40730-014-0009-2
Alhassan A, Sule M, Aliyu S, &aliyu M. Ideal hepatotoxicity model in rats using Carbon Tetrachloride (CCl4). Bayero Journal of Pure and Applied Sciences. 2011;2(2):185–7.
Aithal GP, Watkins PB, Andrade RJ, Larrey D, Molokhia M, Takikawa H, et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther [Internet]. 2011;89(6):806–15. Available from: http://dx.doi.org/10.1038/ clpt.2011.58
Lee G-P, Jeong W-I, Jeong D-H, Do S-H, Kim T-H, Jeong K-S. Diagnostic evaluation of carbon tetrachloride-induced rat hepatic cirrhosis model. Anticancer Res. 2005;25(2A):1029–38.
Fortea JI, Fernández-Mena C, Puerto M, Ripoll C, Almagro J, Bañares J, et al. Comparison of two protocols of carbon tetrachloride-induced cirrhosis in rats – improving yield and reproducibility. Sci Rep [Internet]. 2018;8(1). Available from: http://dx.doi.org/10.1038/ s41598-018-27427-9
Yoshioka H, Usuda H, Nonogaki T, Onosaka S. Carbon tetrachloride-induced lethality in mouse is prevented by multiple pretreatment with zinc sulfate. J Toxicol Sci [Internet]. 2016;41(1):55–63. Available from: http://dx.doi.org/10.2131/jts.41.55
Runyon BA, Sugano S, Kanel G, Mellencamp MA. A rodent model of cirrhosis, ascites, and bacterial peritonitis. Gastroenterology [Internet]. 1991;100(2):489–93. Available from: http://dx.doi. org/10.1016/0016-5085(91)90221-6
Úbeda M, Muñoz L, Borrero M-J, Díaz D, Francés R, Monserrat J, et al. Critical role of the liver in the induction of systemic inf lammation in rats with preascitic cirrhosis. Hepatology [Internet]. 2010;52(6):2086–95. Available from: http://dx.doi. org/10.1002/hep.23961
Suckow MA, Hankenson FC, Wilson RP, Foley PL. The laboratory rat. 2020.
Published
Abstract Display: 507 
PDF Downloads: 412 
